1VanderlindenSJ, ValkenburgHA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for the New York criteria[J]. Arthritis Rheum, 1984,27: 361.
2[1]Mathe G.Thalidomide a drug which may protect the organism against some aggressive effects of the immun_ ologic system[J].Biomed Pharmacother, 2002, 56( 1) :1.
3[2]Zeldis JB, Williams BA, Thomas SD, et al.STEPS: a comprehensive program for controlling and monitoring access to thalidomide[J].Clin Ther, 1999, 21( 2) :319.
4[3]Bauditz J, Wedel S, Lochs H.Thalidomide reduces tumour necrosis factor alpha and interleukin 12 product_ ion in patients with chronic active Crohn's disease[J]. Gut, 2002, 50( 2) :196.
5[4]Diggle GE.Thalidomide: 40 years on[J].Int J Clin Pr_ act,2001,55( 9):627.
6[5]Torano JS, Verbon A, Guchelaar HJ,et al.Quantitative determination of thalidomide in human serum with hi_ gh- performance liquid chromatography using protein precipitation with trichloroacetic acid and ultraviolet detection[J].J Chromatogr B Biomed Sci Appl,1999,734( 2) :203.
8[7]La Maestra L, Zaninoni A, Marriott JB, et al.The thalidomide analogue CC- 3052 inhibits HIV- 1 and tu_ mour necrosis factor- alpha(TNF- alpha)expression in acutely and chronically infected cells in vitro[J].Clin Exp Immunol, 2000, 119( 1) :123.
9[8]Noguchi T, Shimazawa R, Nagasawa K, et al.Thalido_ mide and its analogues as cyclooxygenase inhibitors[J]. Bioorg Med Chem Lett, 2002, 12( 7):1 043.
10[9]Meierhofer C, Dunzendorfer S, Wiedermann CJ.Theor_ etical basis for the activity of thalidomide[J].Bio Dru_ gs, 2001, 15( 10):681.
